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Distal myopathies are genetic primary muscle disorders with a prominent weak-
ness at onset in hands and/or feet. The age of onset (from early childhood to adult-
hood), the distribution of muscle weakness (upper versus lower limbs) and the 
histological findings (ranging from nonspecific myopathic changes to myofibrillar 
disarrays and rimmed vacuoles) are extremely variable. However, despite being 
characterized by a wide clinical and genetic heterogeneity, the distal myopathies 
are a category of muscular dystrophies: genetic diseases with progressive loss of 
muscle fibers. Myopathic congenital arthrogryposis is also a form of distal myopa-
thy usually caused by focal amyoplasia. 
Massive parallel sequencing has further expanded the long list of genes associated 
with a distal myopathy, and contributed identifying as distal myopathy-causative 
rare variants in genes more often related with other skeletal or cardiac muscle 
diseases.
Currently, almost 20 genes (ACTN2, CAV3, CRYAB, DNAJB6, DNM2, FLNC, 
HNRNPA1, HSPB8, KHLH9, LDB3, MATR3, MB, MYOT, PLIN4, TIA1, VCP, 
NOTCH2NLC, LRP12, GIPS1) have been associated with an autosomal dominant 
form of distal myopathy. Pathogenic changes in four genes (ADSSL, ANO5, DYSF, 
GNE) cause an autosomal recessive form; and disease-causing variants in five 
genes (DES, MYH7, NEB, RYR1 and TTN) result either in a dominant or in a re-
cessive distal myopathy. Finally, a digenic mechanism, underlying a Welander-like 
form of distal myopathy, has been recently elucidated. Rare pathogenic mutations 
in SQSTM1, previously identified with a bone disease (Paget disease), unexpectedly 
cause a distal myopathy when combined with a common polymorphism in TIA1. 
The present review aims at describing the genetic basis of distal myopathy and at 
summarizing the clinical features of the different forms described so far.
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Introduction
The term distal myopathy refers to a long list of genetic muscle dis-
eases presenting at the onset with weakness of distal extremities, usually 
combined with progressive atrophy of the corresponding distal muscles. 
Other muscles, including proximal muscles and/or cardiac and respiratory 
muscles, can be affected at a later stage of the disease. The clinical phe-
notype is extremely variable, ranging from severe forms with earlier onset 
and loss of ambulation to very mild late adult onset forms. Other muscle 
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diseases (genetically determined or acquired) may pres-
ent with a distal phenotype, making the diagnostic pro-
cess more complex.
Although two patients with weakness in hands and 
in legs or feet were first described as distal myopathy by 
Gowers over 100 years ago 1, only in 1998 the first genet-
ic defect underlying a distal myopathy was identified  2. 
Ten years ago, in 2010, only fourteen causative genes 
were known. In the last years, massive parallel sequenc-
ing has contributed to identify disease-causing variants 
in novel genes and to elucidate the first example of a di-
genic mechanism causing a distal myopathy (Tab. I). At 
the same time, the number of causative variants, identi-
fied in large resequencing projects, has exponentially 
increased  3-7. Interestingly, most currently known genes 
are also responsible for separate different clinical entities, 
confirming the extreme phenotypic divergence observed 
in the field of genetic myopathies 8. 
More advanced histopathological techniques and re-
fined cell and molecular biology studies have resulted in a 
better understanding of the pathophysiology of distal my-
opathies. Clinical, histopathological, and imaging features 
of each form have been partly clarified, addressing the di-
agnosis, and supporting a proper interpretation in case of 
novel variants identified in previously known genes.
Adult – late onset distal 
myopathies
Welander distal myopathy (WDM) – TIA1
WDM was first described in several Swedish fam-
ilies in 1951 as an autosomal dominant late adult-onset 
(usually over 50 years) disease with a prominent early in-
volvement of fingers and wrist extensors 9. As the disease 
progresses, weakness involves also finger flexors, toe and 
ankle extensors. The disease course is usually slowly pro-
gressive, and patients remain ambulant. Histopathology 
features include rimmed vacuoles.
A missense variant (p.E384K) in TIA1 gene causing 
the disease was identified in 2013  10. TIA1 encodes an 
RNA-binding protein involved in the alternative splic-
ing of specific pre-mRNAs  11-14, and is a key molecule 
in stress granules, regulators of RNA-translation metabo-
lism that show altered dynamics in WDM 10. 
Digenic SQSTM1 and TIA1 mediated distal myopathy
Patients with a Welander distal myopathy phenotype 
but negative for causative rare mutations in TIA1 were 
discovered to have instead a common polymorphism in 
the TIA1, which, with a population frequency of 1%, 
could not be the cause of the disease. Further gene pan-
el sequencing in these patients showed the presence of 
SQSTM1 mutations previously known to cause the Pag-
et’s disease of the bone, a dominant disease with reduced 
penetrance 15. Functional studies showed that the SQSTM1 
gene product, p62, interferes with the same stress granule 
dynamics pathway as TIA1 explaining the background for 
the digenic mechanism  15. This genetic combination of 
rare SQSTM1 causative variants and the common TIA1 
polymorphism did not result in a Paget disease of the 
bone but caused the canonical Welander phenotype. On 
the other hand, a cohort of 50 patients with Paget disease 
of the bone carrying the same SQSTM1 mutations did not 
have the TIA1 polymorphism 15.
Tibial muscular dystrophy (Udd myopathy) – the first 
human titinopathy 
Tibial muscular dystrophy (TMD) or Udd myopathy 
was described in 1993 in Finnish patients  16. Weakness 
in ankle dorsiflexion and atrophy of anterior lower leg 
muscles (often asymmetric) start after age of 35 or much 
later. Progression is slow and walking is usually pre-
served. Extensor digitorum brevis and hand muscles are 
normally spared. Serum CK is normal or mildly elevated 
and muscle imaging shows fatty degeneration in anterior 
tibial muscles and at later stage in all long toe extensors, 
hamstring and medial gastrocnemius muscles.
Muscle biopsy shows myopathic changes with acid 
phosphatase, ubiquitin, p62 and LC3 positive in the af-
fected muscles, but in preserved muscles there is only a 
slight increase of internal nuclei. 
In Finnish TMD patients, a common founder muta-
tion (FINmaj) in the last exon of titin gene (TTN) was 
identified in 2002  17. FINmaj is a complex 11-bp inser-
tion–deletion resulting in substitution of four amino acids 
without any frameshift and preserving the downstream 
amino acid sequence. Following the FINmaj identifica-
tion, missense variants in the same exon (364) were also 
identified in non-Finnish patients 17-19. 
TTN gene encodes titin, the third filament system of 
the sarcomere 20. Titin interacts with several important pro-
teins, including calpain-3 that binds the C-terminal portion 
of titin 21,22. Through a large number of alternative splicing 
events, TTN encodes for a large number of different tran-
scripts, developmental-stage or tissue specific 23,24. Reflect-
ing the size and complexity of titin, causative variants result 
in allelic diseases affecting skeletal muscle, heart or both of 
them, referred to as ‘titinopathies’ 25,26. Dominant titinopa-
thies include the aforementioned TMD, and the hereditary 
myopathy with early respiratory failure (HMERF) caused 
by missense variants in exon 344 17,27-29. Recessive titinop-
athies include a wide spectrum of diseases with a prenatal, 
congenital, childhood or later onset 30,31. A recessive form 
of early/juvenile onset recessive distal titinopathy is further 
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discussed below in this review. With the increasing number 
of reported patients, first insights on the genotype-pheno-
type correlation are achieved 30. TTN variants are also asso-
ciated with dilated and hypertrophic cardiomyopathy 32,33. 
Vocal cord and pharyngeal distal myopathy – MATR3
First described in a large North American family  34 
and later in a large Bulgarian pedigree 35, vocal cord and 
pharyngeal distal myopathy (VCPDM) is characterized 
by adult-onset (between 35 and 60 years) distal weak-
ness and weakness of vocal cord and pharyngeal muscles. 
Limb weakness can be asymmetric and the phenotype is 
highly variable in terms of age of onset, progression and 
muscle weakness distribution 34,36,37. Most patients devel-
op respiratory failure 38. CK levels are normal or mildly 
Table I. List of distal myopathies and causative genes.
Clinical entity Gene(s) Trasmission References
Adult – late onset distal myopathies
Welander distal myopathy TIA1 AD Hackman et al., 2012
Digenic SQSTM1 and TIA1 mediated distal 
myopathy
SQSTM1+TIA1 DG Lee et al., 2018
Tibial muscular dystrophy (Udd myopathy) TTN AD Hackman et al., 2002
Vocal cord and pharyngeal distal myopathy MATR3 AD Senderek et al., 2009
Distal Actininopathy ACTN2 AD Savarese et al., 2019
Distal Myopathy with sarcoplasmic bodies MB AD Olive et al., 2019
Oculopharyngeal distal myopathy NOTCH2NLC, 
LRP12 and GIPC1 
AD Deng et al., 2020; Ishiura 
et al., 2019; Saito et al., 
2020; Sone et al., 2019
PLIN4 mutated distal myopathy PLIN4  AD Ruggieri et al. 2020
VCP distal myopathy VCP AD Palmio et al 2011
Myofibrillar distal myopathies
Distal myopathy with myotilin defect MYOT AD Penisson-Besnier et al., 
2006 
Late onset distal myopathy 
(Markesbery-Griggs, Zaspopathy)
LDB3 AD Griggs et al., 2007
Desminopathy DES AD > AR Sjoberg et al.,  1999
Alpha-B crystallin-mutated distal myopathy CRYAB AD Reichlich et al. 2010
Early adult onset distal myopathies
Miyoshi myopathy DYSF AR Liu et al., 1998
Recessive distal titinopathy TTN AR Evila et al., 2017
Distal myopathy with rimmed vacuoles 
(Nonaka and GNE myopathy)
GNE AR Kayashima et al., 2002
Distal ABD-filaminopathy FLNC AD Duff et al., 2011
DNAJB6 distal myopathy DNAJB6 AD Ruggieri et al., 2015 - 
Palmio et al., 2020
Rimmed vacuolar neuromyopathy HSPB8  AD Ghaoui et al., 2016
ANO5 distal muscular dystrophy ANO5 AR Bolduc et al., 2010
RYR1 mutated calf predominant distal myopathy RYR1 AD/AR Laughlin et al., 2017 - 
Jokela et al., 2019
Early-childhood onset distal myopathies
Early onset distal myopathy (Laing) MYH7 AD > AR Meredith et al., 2004
Early onset distal myopathies with nebulin defect NEB AR > AD Wallgren-Pettersson et al., 
2007, Kiiski et al., 2019
Early onset ADSSL distal myopathy ADSSL AR Park et al., 2016
Early onset distal myopathy with KLHL9 mutations KLHL9 AD Cirak et al., 2010
Other myopathies and dystrophies with distal weakness
Distal myopathy with caveolin defect CAV3 AD Tateyama et al., 2002
DNM2 related distal myopathy DNM2 AD Bitoun et al., 2005
AD: autosomal dominant; AR: autosome recessive; DG: digenic
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elevated. EMG shows myopathic changes and rimmed 
vacuoles are present in the biopsy. Muscle MRI shows a 
predominant involvement of the lower legs both anterior 
and posterior compartment and hamstrings in thighs 39. 
The underlying re-occurring p.S85C mutation was 
identified in MATR3 gene  35. MATR3 encodes matrin-3, 
a protein located in the nuclear matrix where it regulates 
several processes related to gene expression, RNA splic-
ing and export of RNA and nuclear proteins 40,41. Variants 
in MATR3 have also been identified in patients with amy-
otrophic lateral sclerosis (ALS) 42. 
Distal Actininopathy – ACTN2 
Distal actininopathy is an autosomal dominant, adult 
onset distal myopathy starting usually with foot drop. The 
disease later progresses to proximal lower limb muscles 
while upper limbs remain relatively spared  43. Serum 
CK levels are mildly elevated and muscle biopsy shows 
rimmed vacuoles with some myofibrillar disarrays and 
undulation of the Z-disk on electron microscopy 43. 
The underlying genetic defects in the four families 
reported so far are heterozygous missense variants in the 
ACTN2 gene. ACTN2 encodes alpha-actinin2, a structural 
molecule of the Z-disks that interacts with titin and acts 
a scaffold of many other Z-disk located proteins such as 
myotilin 44-47.
Variants in ACTN2 also cause congenital myopathy 
with structured cores and Z-line abnormalities 48. More-
over, dilated cardiomyopathy and hypertrophic cardio-
myopathy have been associated with missense variants in 
ACTN2 49-53.
Distal Myopathy with sarcoplasmic bodies – MB
In 1980 Edström et al. published a Swedish family 
with this title  54. Only recently, the genetic cause of the 
disease was identified with one unique causative variant 
in Myoglobin (MB), reoccurring in several unrelated fam-
ilies  55. In these later studied families, the characteristic 
muscle pathology was evident but the clinical phenotype 
was more proximo-distal and not particularly distal 55. 
Oculopharyngeal distal myopathy OPDM – CGG and 
GGC expansions
The peculiar combination of severe adult onset distal 
atrophies in limb muscles and facial weakness, ptosis and 
dysphagia can occur both in dominant and recessive fam-
ilies and in sporadic patients 56,57. In the studied patients, 
the muscle pathology is a rimmed vacuolar myopathy. 
In the two last years the cause of many Asian dominant 
families have been clarified as caused by triplet repeat ex-
pansions, both CGG and GGC, in three different genes 
NOTCH2NLC, LRP12 and GIPC1  58-61. The repeats are 
translated into aggregating protein products and the host 
gene functions are not supposed to contribute to the dis-
ease mechanism.
PLIN4 mutated distal myopathy – PLIN4
A large Italian family with an autosomal dominant 
adult-onset distal myopathy and histopathological fea-
tures of rimmed vacuoles was first described in 2004 62. 
Linkage analysis suggested that the causative gene could 
have been localized in the 19p13.3 locus 62.
Recently, Ruggieri et al. identified the underlying 
genetic defect in the PLIN4 gene, encoding for perili-
pin-4  63. Thirty-one repeats of 99 nucleotides in exon 4 
of PLIN4 encode the 31x33 amino acid amphipathic do-
main of perilipin-4. An expansion of the normal repeat to 
40 × 99 bases, resulting in 297 (9 × 33) extra amino acids, 
has been identified in the affected members of the family.
Perilipin-4 is a member of the perilipin family, a 
group of proteins that coat the surface of lipid droplets 64. 
Perilipin-4 is highly expressed in skeletal muscle with a 
possible role in lipid metabolism. The identified repeat 
expansion in patients with PLIN4-related distal myopathy 
seems to cause a misfolding and leads to protein accu-
mulation in vacuoles disrupting the myofibrillar organi-
zation 63. 
VCP distal myopathy – VCP
Initially described by Palmio and colleagues in a 
large dominant Finnish family, VCP-related distal myop-
athy has an onset in mid-adulthood mainly affecting ante-
rior leg muscles 65. After 25 years of disease, the patients 
became affected by a progressive frontotemporal demen-
tia. None of the patients had signs of Paget disease of the 
bone. Serum CK levels are normal or slightly elevated. 
Myopathic changes with rimmed vacuoles are observed 
in the muscle biopsy. MRI shows degenerative changes 
of anterior lower leg muscles. 
Although a clinical variability has been observed 66-
73, the most common phenotype of pathogenic VCP vari-
ants is proximal myopathy with scapular winging, Paget 
disease and frontotemporal dementia (IBMPFD) 74-76.
Myofibrillar distal myopathies
Distal myopathy with myotilin defect – MYOT
A late-onset distal myopathy has been associated 
with heterozygous variants in MYOT gene 77-79. The first 
symptoms, weakness of ankle dorsiflexion and/or calf 
muscles, occur after age 50 years but, despite late onset, 
the further progression can be rapid. Respiratory and car-
diac muscles are spared.
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Histopathological features are consistent with myo-
fibrillar myopathy and include rimmed and non-rimmed 
vacuoles, and myofibrillar disorganization with myotilin 
accumulations 79-81. Muscle imaging shows that soleus is 
typically the first muscle affected followed by tibialis an-
terior and gastrocnemius medialis muscles 82,83.
The most common causative variants in MYOT are 
missense changes affecting serine and threonine amino 
acids in the serine rich domain. MYOT gene encodes my-
otilin, a key component of the Z-disc, directly binding 
F-actin 84. Some patients have been described as affected 
by a dominant limb-girdle muscular dystrophy (previous-
ly LGMD1A) 85,86, but distal myopathy is the main phe-
notype. A proximal muscle involvement is only observed 
in later stages or in homozygosity for known dominant 
variants 87,88. The term ‘spheroid body myopathy’ was al-
so used since the protein aggregates in some cases have 
the corresponding shape 89,90.
Late onset distal myopathy (Markesbery-Griggs, 
Zaspopathy) – LDB3
The dominant LDB3-related distal myopathy usually 
starts with ankle weakness after the age of 40 years with 
later involvement of proximal muscles 91-94. Cardiomyop-
athy can occur very late; facial and respiratory muscles 
are preserved. Muscle biopsy reveals myofibrillar myopa-
thy with rimmed and non-rimmed vacuoles 95. Myofibril-
lar protein accumulations are similar with myotilinopathy 
and desminopathy 96.
LDB3 encodes the lim domain-binding 3 protein, 
also called Z-band alternatively spliced PDZ motif-con-
taining protein (ZASP) that interacts with other Z-disk 
proteins 97,98. Hypertrophic and dilated cardiomyopathies 
(with or without left ventricular noncompaction) are al-
lelic disorders 99,100.
Desminopathy – DES
Desmin-related distal myopathy is a myofibrillar my-
opathy with cytoplasmic accumulation of desmin in car-
diac and skeletal muscles. The first family was described 
in 1943 long before the gene was known  101,102. Cardio-
myopathy and cardiac conduction defects are frequent, 
and the weakness/atrophy involves both hands and lower 
legs with later spread to proximal muscles. MRI shows 
the early involvement of peroneal muscles followed by 
tibialis anterior, gastrocnemius and soleus muscles  80,82. 
CK is usually slightly elevated. 
The fist causative variants in DES were identified in 
1998 103. DES encodes desmin, a protein of the interme-
diate filament connecting Z-band with the plasmalemma 
and the nucleus104. As suggested by a recent study, desmin 
forms seeding-competent amyloid that is toxic to myofi-
bers and disease-causing mutations enhance the amyloid 
formation 105. Most patients have a dominant disease with 
onset in early adulthood but a later onset is possible 106. 
Rare cases with a recessive, more severe, form have been 
reported  107. Dominant cardiomyopathy without skeletal 
muscle disease, scapuloperoneal and other phenotypes, 
due to the increasing number of causative variants identi-
fied, are also reported 108-112.
Alpha-B crystallin-mutated distal myopathy – CRYAB
In 1998, Vicart and colleagues identified the first 
causative variant in the CRYAB gene causing a myopathy 
with accumulation of aggregates of desmin 113. In 2003, 
Selcen et al described patients with a generalized proxi-
mal and distal myopathy affecting also the cardiac and re-
spiratory function and carrying mutations in CRYAB 114D. 
In 2010 and in 2012, two studies identified patients with 
CRYAB mutations and a distal adult-onset myofibrillar 
myopathy  115,116. CRYAB-related distal myopathy main-
ly involves the anterior part of the distal leg at the early 
stage and progresses with a milder proximal weakness. 
Cataracts are the hallmark and dysphagia, dysphonia, re-
spiratory failure, and cardiomyopathy may be associated. 
Muscle MRI shows fatty degenerative changes in tibia-
lis anterior, gastrocnemius medialis muscles and vastus 
muscles 82,115,117,118. 
CRYAB encodes alpha-B-crystallin, also called 
HSPB5, a member of the small heat-shock protein family, 
a molecular chaperone that interacts with desmin in the 
assembly of intermediate filaments 119-122.
Causative CRYAB variants also cause a dominant di-
lated cardiomyopathy, congenital cataract (dominant and 
recessive) and a more severe, usually recessive myopathy 
(fatal infantile hypertonic myofibrillar myopathy) 123-127.
Early adult onset distal 
myopathies
Miyoshi myopathy – DYSF
Miyoshi and colleagues first described patients in the 
sixties with early adult-onset weakness, myalgia and at-
rophy in calf muscles  128. Serum creatine kinase (CK) is 
highly elevated already in the early stages of the disease or 
even in presymptomatic patients. Muscle imaging shows 
marked involvement of posterior lower legs. Muscle biop-
sy shows myopathic changes with necrotic fibers in the calf 
muscles and inflammation is a common finding. 
Dysferlin (DYSF) as causative gene with biallelic 
recessive mutations was identified in 1998  2. Dysferlin 
is a ubiquitous transmembrane protein with a high skel-
etal muscle expression. The protein most probably acts 
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in calcium-mediated sarcolemmal fusion events and re-
sealing 129-131. Dysferlin expression by immunostaining or 
western blot (even from blood leucocytes) is useful in the 
diagnostic process, although the protein can be also sec-
ondarily reduced 132,133.
Myoshi myopathy and LGMDR2 Dysferlin-related 
(previously LGMD2B), one of the most common LGMD 
form in several countries 4,134,135, are allelic diseases with 
overlapping symptoms and signs  136,137. LGMD patients 
have a more proximal involvement at the onset but, after 
20 years of disease progression, the two phenotypes usu-
ally merge as dysferlinopathies 138-140.
Recessive distal titinopathy – TTN
Some nonsense, small indels causing a frameshift or 
splice site variants in the last and second last exons of 
TTN, initially also thought to cause dominant TMD be-
cause of dominant-looking pedigrees, later proved to be 
recessive 141-145. The presence of second causative variants 
in trans explains the novel entity of early/juvenile onset 
recessive distal titinopathy, a more severe condition than 
the late onset TMD 141-143. In some families, multiple sec-
ond causative variants segregating with the disease would 
mimic the presence of a dominant inheritance, making 
the diagnosis even more complex 141,142,146. 
The complexity of TTN gene may result in elusive 
variants not identified on DNA by the traditional pipe-
lines  147. Second tier tests, such as copy number variant 
(CNV) analysis and RNA sequencing, contribute to iden-
tify unrecognized pathogenic variants 148-152. 
Distal myopathy with rimmed vacuoles (Nonaka or GNE 
myopathy) – GNE
Independently described by Nonaka et al. and by Ar-
gov and Yarom, the GNE distal myopathy is a rimmed 
vacuolar recessive myopathy with an early adult on-
set 153,154. It first affects the anterior compartment of low-
er legs and thigh hamstring muscles with sparing of the 
quadriceps, but the progression is rather severe, and half 
of the patients loose ambulation within 10 years. Serum 
creatine kinase is mildly elevated and muscle histopathol-
ogy is characterized by rimmed vacuoles. 
The causative gene (GNE) was identified in 2001 155 
and, since then, patients have been reported worldwide. 
GNE encodes an epimerase-kinase enzyme involved in 
the sialic acid biosynthesis. Glycoproteins and glycolip-
ids located in the membrane often undergo a sialic ac-
id modification that seems to be crucial for their func-
tion  156. Nevertheless, in a recent study, no consistent 
major change in sialylation has been observed comparing 
patients and matched control samples, suggesting that the 
pathophysiology of the disease is still unclear 157.
More than 180 variants are currently known and 
founder mutations first reported from Middle East and Ja-
pan have been described in many populations 158-163. GNE 
is susceptible to Alu-mediated recombination, and copy 
number variants (CNV) have been reported suggesting 
the utility of second-tier tests in case of an uninformative 
sequencing analysis aiming at the identification of single 
nucleotide variants  164-167. Moreover, a vast clinical het-
erogeneity, only partly explained by the GNE genotype, is 
observed in families with GNE mutations 160,168-170. 
Sialuria is an allelic dominant metabolic disease 
characterized by the accumulation of N-acetylneuraminic 
acid (NeuAc) due to missense variants in GNE 171.
Distal ABD-filaminopathy – FLNC
A large Australian family with a dominant, adult-on-
set, slowly progressive distal myopathy was described in 
2005 by Williams and colleagues 172. In a second Italian 
family with otherwise similar phenotype reported by Duff 
et al. cardiac involvement was also present 173. Weakness 
of handgrip is the usual presentation followed by calf 
muscle plantar flexion weakness. The progression is slow, 
and patients remain ambulant. CK is normal or mildly 
elevated, and muscle MRI shows fatty replacement in 
posterior compartment of lower legs. Histopathology is 
unspecific myopathic without vacuoles or myofibrillar 
abnormalities. 
Combining linkage data and resequencing of candi-
date genes in these two families, two different missense 
changes in the N-terminal actin-binding domain (ADB) of 
FLNC were identified 173. The FLNC gene encodes filamin, 
an actin ligand that plays an important role in mechanical 
stabilization, mechanosensation and intracellular signal-
ling through a large network of interactors 174,175. Mutations 
in other parts of the gene may cause late onset myofibrillar 
myopathy with generalized weakness and cardiomyopa-
thy 176-178. After the gene identification in 2011, novel FL-
NC causative variants have been identified, expanding the 
spectrum of FLNC-related myopathies 179-181. 
Recent findings suggest a more complex gen-
otype-phenotype correlation. A missense variant, 
p.M222V, in the N-terminal actin-binding domain, caus-
ing a distal myofibrillar myopathy, has been reported 182. 
Another missense change, p.C203Y, has been recently 
found to cause an upper limb distal myopathy with ne-
maline bodies 183. 
DNAJB6 distal myopathy – DNAJB6
The disease was originally reported by Servidei and 
colleagues in a large Italian family with onset of ankle 
weakness between the second and sixth decades of life 184, 
and usually progressing to proximal muscles and upper 
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limbs. Muscle biopsy showed dystrophic changes and 
rimmed vacuoles. In the Italian family, the causative vari-
ant was found in DNAJB6, in a different locus from the 
one initially reported 185. DNAJB6 encodes a ubiquitously 
expressed member of the DNAJ/HSP40 family of co-chap-
erones  119,186. Mutations in DNAJB6, specifically in the 
G/F domain, cause more often a proximal myopathy (LG-
MD1D) 187-193. Recently, a form of DNAJB6-related distal 
calf-predominant myopathy has been reported in patients 
with particular mutations in the N-terminal J-domain 194. 
Rimmed vacuolar neuromyopathy – HSPB8
Ghaoui and colleagues reported two families with 
a dominant HSPB8-related disease showing early adult 
neurogenic leg weakness and progressing towards a dis-
tal and proximal myofibrillar and rimmed vacuolar my-
opathy in the later stage of the disease 195. EMG revealed 
denervation in the distal lower limbs and myopathic prox-
imal changes. MRI of the lower limb muscles showed 
first diffuse neurogenic changes in gastrocnemius, deep 
toe flexors, and peroneus with later fatty replacement in 
proximal thigh and lower legs muscles.
The HSPB8 gene encodes the small heat-shock pro-
tein-beta 8, acting as stress protein with a chaperone-like 
activity and part of the chaperone-assisted selective auto-
phagy (CASA) complex 119,196. HSPB8 missense variants 
had been previously associated with distal hereditary mo-
tor neuropathy 2A (dHMN2A) and Charcot-Marie-Tooth 
disease (CMT2L) 197-201. The myofibrillar myopathy with 
aggregates and rimmed vacuoles mimics the histopatho-
logical changes seen in myopathies caused by defects in 
BAG3 and DNAJB6 202,203. 
Later other families with a combined neuromuscu-
lar disorder, encompassing dHMN and MFM have been 
described204. In one family decrease of TARDBP mRNA 
levels causing a consistent alteration of TDP‐43‐depen-
dent splicing was reported 204. Recently, a novel HSPB8 
variant has been found in a patient with limb-girdle my-
opathy without associated neuropathy 205.
ANO5 distal muscular dystrophy – ANO5
Distal anoctaminopathy has an age of onset in early/
mid adulthood (18-40 years)  206,207. Early manifestations 
include difficulties in sport activity and in walking on tip-
toes but often the clinical presentation is mild, or the dis-
ease does not even result in overt clinical signs. The early 
stage hypertrophy of calf muscles progresses into muscle 
atrophy 208. At a later stage, proximal muscle weakness and 
wasting is observed. Typically, the cardiac muscle is spared. 
CK levels are usually highly elevated (over 10 times the up-
per limits). Non-specific myopathic changes with scattered 
necrotic fibers are observed in the muscle biopsy. 
The disease is due to bi-allelic causative variants in 
the ANO5 gene, encoding for anoctamin-5, a putative cy-
toplasmic calcium-activated chloride channel, with a pos-
sible role in membrane fusion and repair 209,210. The more 
common phenotype of bi-allelic variants in ANO5 is late 
onset proximal (LGMDR12)  206,207,211-214. Variants causing 
ANO5-related recessive anoctaminopathies mostly result 
in a reduced protein expression and missense changes like-
ly destabilize the protein, causing its degradation 215,216. We 
still lack a clear genotype-phenotype correlation explain-
ing the high intrafamilial and interfamilial clinical variabil-
ity observed, also considering that female patients often 
have a milder disease than males 206,212,217-221. 
A dominant form of gnathodiaphyseal dysplasia is 
(GDD) an allelic disorder caused by ANO5 missense vari-
ants in heterozygosity  222,223. The pathomechanism of the 
ANO5-related GDD is still unclear. However, the protein 
seems to have an important role in the embryonic develop-
ment and most probably in the osteoblast differentiation 223.
RYR1 mutated calf predominant distal myopathy – RYR1
A very mild dominant distal myopathy with prefer-
ential fatty degeneration of medial gastrocnemius, clearly 
shown by muscle MRI, has been recently reported in one 
Italian and two Finnish families 224. Some patients exhibit 
toe walking in the childhood with spontaneous remission. 
In adulthood, patients complain of exercise myalgia in the 
calves, and show 5-10 fold elevated CK. No limitation 
of walking was present even in elderly patients. Mus-
cle biopsy reveals core pathology. Three different RYR1 
mutations were identified in different parts of the gene, 
which encodes ryanodine receptor 1, a calcium release 
channel of the sarcoplasmic reticulum that, together with 
sarcolemmal voltage-gated calcium channels (DHPR), is 
responsible for the excitation-contraction coupling.
Dominant and recessive mutations in the RYR1 gene 
present with a multitude of phenotypes including malig-
nant hyperthermia (MH) susceptibility and congenital 
central core disease (CCD), centronuclear myopathy, 
multiminicore myopathy, congenital fibre type dispropor-
tion, axial myopathy, King-Denborough syndrome, atyp-
ical periodic paralysis and exertional rhabdomyolysis/
myalgia  225-235. A childhood-onset distal myopathy pre-
senting with hand stiffness and facial weakness has been 
associated to bi-allelic RYR1 variants 236. 
Early-childhood onset distal 
myopathies
Early onset distal myopathy (Laing myopathy) – MYH7
Laing myopathy was the first distal myopathy with 
established genetic linkage 237. The onset is in early child-
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hood with the ankle dorsiflexor and toe extensor (hanging 
big toe) weakness and the disease has a slow progression. 
Severe forms develop scoliosis and involves proximal, 
neck and facial muscles. CK levels are normal or mildly 
elevated. The most consistent histopathology is hypot-
rophy of type 1 slow fibers, often combined with core/
minicore lesions 238. Muscle MRI shows the involvement 
of anterior compartment lower leg muscles and, eventu-
ally, of the sartorius, with relative sparing of the lateral 
gastrocnemius muscle and rectus femoris 239-242.
In 2004 the causative variant was identified in the 
MYH7 gene encoding the beta heavy chain of myosin 243. 
Since then, a large number of causative variants in the tail 
of the protein were reported, with a large proportion (30%) 
of re-occurring de novo mutations masking the dominant 
effect of the variants 244-248. Causative variants in the head 
and neck domains at the N-terminal of the protein have 
been mainly associated with hypertrophic cardiomyopa-
thy (without skeletal muscle involvement) 249-251. Variants 
in the ultimate C-terminal region most often result in oth-
er skeletal myopathies (hyaline body myopathy) with or 
without cardiac involvement 252,253. Rare recessive forms 
of MYH7-related myopathy have been reported 254-256.
Early onset distal myopathies with nebulin defect – NEB
Bi-allelic, mainly missense, variants in NEB gene 
may result in an early-onset distal myopathy with a pre-
dominant weakness of extensor muscles of feet and later 
hands  257,258. The progression is very slow and adult pa-
tients do not have major disability.
Muscle imaging shows a selective fatty degeneration 
in the anterior tibial muscles, EMG is myopathic and 
CK is normal or mildly elevated. Scattered and grouped 
atrophic fibers (that can be misinterpreted as neurogenic 
changes) are detectable in the biopsy of affected muscle 
without rods on light microscopy 258,259. Small rods asso-
ciated with Z-disks may be present on electron micros-
copy 259.
A large in-frame deletion, dominantly inherited in a 
three-generation family with a distal nemaline rod/cap 
myopathy, was recently described  260. The in-frame de-
letion results in a protein of reduced size with a domi-
nant-negative effect  260. Patients present with foot drop 
in childhood and the disease progresses with the involve-
ment of distal upper limbs. CK can be slightly elevated, 
EMG is myopathic and muscle MRI shows fatty degen-
eration of the anterior compartment lower leg muscles. 
A large heterozygous de novo deletion in young patient 
with asymmetric distal and facial weakness has just been 
identified confirming the dominant effect of an abnormal 
protein (submitted). 
The 183-exon NEB gene encodes nebulin, a protein 
of 600-900   kDa that regulates the length of actin fila-
ments 261,262. Causative variants in NEB (mainly nonsense, 
out-of-frame indels or copy number variants, and splicing 
variants) are the most common cause of congenital nema-
line myopathy 263,264. Additional allelic diseases are core 
rod myopathy, and fetal akinesia/lethal multiple pterygi-
um syndrome 259,265,266. 
Copy number variant (CNV) analysis and RNA se-
quencing are essential to identify possible elusive patho-
genic NEB variants 148-150,267,268. 
Early onset ADSSL distal myopathy – ADSSL
In 2016, Park and colleagues reported two unrelat-
ed Korean families with an autosomal recessive adoles-
cent-onset distal myopathy with facial muscle weakness, 
mild CK elevation and rimmed vacuoles in the muscular 
biopsy  269,270. Two different variants in the ADSSL gene 
were identified by exome sequencing. The ADSSL gene 
encodes the muscle isozyme of adenylosuccinate syn-
thase, the enzyme catalysing the initial reaction in the 
conversion of inosine monophosphate (IMP) to adenos-
ine monophosphate (AMP) 271,272. Two following studies 
identified novel Korean and non-Korean (Turkish and 
Indian) patients, confirming the gene-disease associa-
tion 273,274. Most patients presented with a distal myopathy 
with onset in childhood or adolescence progressing to in-
volve weakness of proximal muscles in early adulthood. 
However, one patient, homozygous for a missense vari-
ant, shows a proximal myopathy with contractures and 
muscle atrophy, expanding the ADSSL-related spectrum 
of phenotypes 274.
Early onset distal myopathy with KLHL9 mutations – KLHL9
Cirak and colleagues described a German family 
with an autosomal distal weakness caused by a heterozy-
gous variant in the KLHL9 gene 275. Despite extensive lat-
er studies, this gene has not been confirmed in any other 
myopathy families.
Other myopathies and dystrophies 
with distal weakness
Distal myopathy with caveolin defect – CAV3
In 2002, Tateyama and colleagues described a form 
of sporadic distal myopathy caused by an heterozygous 
missense variant in CAV3 gene 276. Since then, additional 
patients and further causative variants have been report-
ed 277,278. Onset is in early adulthood, muscle atrophy and 
weakness are often limited to the small muscles of the 
hands and feet. Other features included calf hypertrophy, 
pes cavus, myalgias, slightly increased serum CK. EMG 
studies show a myopathic pattern and histological find-
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ings include nonspecific myopathic changes 278,279. CAV3 
expression can be reduced.
Variants in CAV3 can also cause an isolated hyper-
ckemia or a rippling muscle disease 280-285 and even car-
diac phenotypes (hypertrophic cardiomyopathy and long 
QT syndrome)  286,287. Some patients with CAV3 related 
myopathy have been previously described as LGMD1C 
patients 288.
DNM2 related distal myopathy – DNM2
DNM2-related myopathy is an autosomal dominant 
slowly progressive centronuclear myopathy characterized 
by the presence of centrally located nuclei in a several 
muscle fibres  289. The clinical onset is usually in child-
hood or early adulthood 290. The distal muscle weakness 
is marked although facial weakness is the clinical lead to 
diagnosis 291-300. More severe forms, clinically resembling 
myotubular myopathy, have been described 301. MRI stud-
ies shows fatty infiltration of the calf muscles 302. Electro-
myography may show a mix pattern with myopathic and 
neuropathic changes. 
DNM2 encodes dynamin 2, a ubiquitously expressed 
GTPase that is involved in endocytosis and intracellular 
trafficking 303-306. Dynamin 2 interacts with actin and has 
an active role in regulating microtubule networks and in 
centrosome function 307. DNM2 mutations can also cause 
an intermediate or axonal CMT disease with and without 
cataracts  308. A lethal congenital syndrome associating 
akinesia, joint contractures, hypotonia, skeletal abnor-
malities, and brain and retinal haemorrhages has been ob-
served in three consanguineous families with a missense 
variant (p.Phe379Val) in homozygosity 309.
Differential diagnostics 
A long range of other myopathies needs to be consid-
ered in the differential diagnostics since they may show 
prominent distal weakness and/or atrophy:
• Facioscapulohumeral muscular dystrophy;
• Myotonic dystrophy type1;
• HMERF titinopathy (i.e. p.C31712R mutation);
• Scapuloperoneal syndromes (FHL-1, TRIM32,…);
• Other nemaline and rod-core myopathies (TPM2, 
ACTA1,…);
• Inclusion body myositis;
• Telethoninopathy;
• Glycogenoses: brancher and debrancher enzyme de-
fects;
• Lipidosis in PNPLA2 mutated disease;
• Mitochondrial distal myopathy (POLG1);
• Nephropathic cystinosis;
• Amyloid myopathy (myeloma induced).
Conclusions
Despite the huge developments in the last 20 years to 
uncover the genetic cause of distal myopathy, some fam-
ilies and patients still remain without a final diagnosis. 
The introduction of long read sequencing and RNA se-
quencing in clinical care and the constitution of large in-
ternational consortia will most probably further increase 
the diagnostic rate 310-316. 
The reason for some genetic defects to have prefer-
ence for the distal limb muscles in causing loss of muscle 
tissue is unclear and understanding the molecular back-
ground for this preference may also harbour insight for 
therapeutic opportunities.
Considering the crucial advancements in the last de-
cade, we can look forward optimistically to the upcom-
ing decade. We will most probably identify an increasing 
number of digenic diseases and of genetic and non-ge-
netic modifiers influencing the phenotype. The next chal-
lenge is to translate the genetic and molecular advance-
ments in clinics, thereby contributing to the development 
of a personalized medicine aiming at providing a tailored 
approach to each patient with a distal myopathy 317,318. 
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